Genus plc (GNS) Receives Buy Rating from N+1 Singer
GNS has been the subject of a number of other research reports. Peel Hunt reissued a buy rating and set a GBX 2,600 ($34.20) target price on shares of Genus plc in a research note on Wednesday. Liberum Capital restated a hold rating and set a GBX 2,100 ($27.62) price target on shares of Genus plc in a research report on Monday, October 9th. Finally, Kepler Capital Markets restated a hold rating and set a GBX 2,353 ($30.95) price target on shares of Genus plc in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of GBX 2,270.60 ($29.86).
Genus plc (LON:GNS) traded down GBX 19 ($0.25) during mid-day trading on Thursday, hitting GBX 2,192 ($28.83). 26,320 shares of the stock were exchanged, compared to its average volume of 51,668. Genus plc has a twelve month low of GBX 1,652 ($21.73) and a twelve month high of GBX 2,500 ($32.88).
The firm also recently declared a dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 16th will be given a dividend of GBX 16.20 ($0.21) per share. The ex-dividend date of this dividend is Thursday, November 16th. This is a positive change from Genus plc’s previous dividend of $7.40. This represents a yield of 0.83%.
Genus plc Company Profile
Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk. The Company’s segments include Genus PIC, Genus ABS, Genus Asia, and Research and Development. The Genus PIC segment is engaged in porcine sales business, excluding Asia, and serves porcine customers in North America, Latin America and Europe.
Receive News & Ratings for Genus plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus plc and related companies with Analyst Ratings Network's FREE daily email newsletter.